Ishara Investments LP Makes New $1.46 Million Investment in Silence Therapeutics PLC Sponsored ADR $SLN

Posted by Francis Steltz on Jun 18th, 2026

Ishara Investments LP purchased a new stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 240,000 shares of the company’s stock, valued at approximately $1,459,000. Silence Therapeutics comprises about 1.7% of Ishara Investments LP’s holdings, making the stock its 20th biggest position. Ishara Investments LP owned about 0.51% of Silence Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Boothbay Fund Management LLC lifted its position in shares of Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Silence Therapeutics by 6.6% during the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after buying an additional 3,935 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after buying an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares during the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Silence Therapeutics by 4.4% during the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after buying an additional 6,692 shares during the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SLN has been the subject of several analyst reports. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $55.00.

Check Out Our Latest Research Report on SLN

Silence Therapeutics Stock Up 0.7%

Shares of Silence Therapeutics stock opened at $6.76 on Thursday. The firm has a market capitalization of $319.34 million, a P/E ratio of -4.25 and a beta of 1.48. The company has a 50 day moving average price of $6.76 and a 200 day moving average price of $6.10. Silence Therapeutics PLC Sponsored ADR has a 52 week low of $4.19 and a 52 week high of $8.40.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The company had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $1.26 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. As a group, research analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current fiscal year.

Silence Therapeutics Company Profile

(Free Report)

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.